A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

Also called NCT04028518

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04028518
Other papers using this trial's data
  • Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial Stroke, 2024-02 DOI, PubMed 38152962

Courtesy of the U.S. National Library of Medicine.

Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04028518. Randomized; no masking; primary purpose treatment. Start 2019-07-20 (anticipated); primary completion 2020-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
Condition
Acute Ischemic Stroke
Intervention (Drug)
r-PA
Intervention (Drug)
r-PA
Intervention (Drug)
Alteplase for Injection
Lead sponsor
Angde Biotech Pharmaceutical Co., Ltd. (class: industry)
Collaborator
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct04028518
Content hash
1757bc71efd5c3cc0155f33138890d713e8a9c0d732c3444fd0f7a2b6ddae4fc